You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Luye Innomind Pharma Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for LUYE INNOMIND PHARMA, and when can generic versions of LUYE INNOMIND PHARMA drugs launch?

LUYE INNOMIND PHARMA has one approved drug.

There is one US patent protecting LUYE INNOMIND PHARMA drugs.

There are seven patent family members on LUYE INNOMIND PHARMA drugs in six countries and five supplementary protection certificates in three countries.

Summary for Luye Innomind Pharma
International Patents:7
US Patents:1
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Luye Innomind Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Luye Innomind Pharma ERZOFRI paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 216352-005 Jul 26, 2024 RX Yes Yes 11,666,573 ⤷  Sign Up ⤷  Sign Up
Luye Innomind Pharma ERZOFRI paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 216352-002 Jul 26, 2024 RX Yes Yes 11,666,573 ⤷  Sign Up ⤷  Sign Up
Luye Innomind Pharma ERZOFRI paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 216352-001 Jul 26, 2024 RX Yes Yes 11,666,573 ⤷  Sign Up ⤷  Sign Up
Luye Innomind Pharma ERZOFRI paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 216352-004 Jul 26, 2024 RX Yes Yes 11,666,573 ⤷  Sign Up ⤷  Sign Up
Luye Innomind Pharma ERZOFRI paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 216352-003 Jul 26, 2024 RX Yes Yes 11,666,573 ⤷  Sign Up ⤷  Sign Up
Luye Innomind Pharma ERZOFRI paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 216352-006 Jul 26, 2024 RX Yes Yes 11,666,573 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Luye Innomind Pharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0368388 SPC/GB07/065 United Kingdom ⤷  Sign Up PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
0904081 11C0035 France ⤷  Sign Up PRODUCT NAME: PALMITATE DE PALIPERIDONE; REGISTRATION NO/DATE: EU/1/11/672/001 20110304
0904081 SPC/GB11/044 United Kingdom ⤷  Sign Up PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
0368388 07C0044 France ⤷  Sign Up PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625
0904081 2011/021 Ireland ⤷  Sign Up PRODUCT NAME: PALIPERIDONE PALMITATE ESTER; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.